Premium
Altered in vitro uptake of the radiolabelled antiviral imaging “probe” e‐5‐(2‐ 125 iodovinyl)‐2′‐deoxyuridine following administration of acyclovir
Author(s) -
Klapper Paul E.,
Lewis Alfor G.,
Cleator Graham M.,
Templeton Phillip,
Longson Maurice
Publication year - 1989
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890280107
Subject(s) - in vivo , in vitro , aciclovir , virology , deoxyuridine , encephalitis , virus , intracellular , drug , antiviral drug , medicine , pharmacology , herpesviridae , viral disease , biology , biochemistry , dna , microbiology and biotechnology
Current developments in the use of radiolabelled antiviral drugs as specific “probes” for virus‐infected cells in vivo may allow the specific neuroradiological diagnosis of herpes encephalitis. As “blind therapy” with the antiviral drug acyclovir may precede specific neuroradiological diagnosis, the aim of the present study was to investigate whether or not acyclovir interferes with the uptake of the radioprobe E‐5‐(2‐ 125 lodovinyl)‐2′‐deoxyuridine (rlVDU) by virusinfected cells in vitro. Acyclovir treatment (0.1 to 10 m̈g/ml) was shown to increase initial radioprobe uptake by virus‐infected cells. However, with continued incubation in the presence of acyclovir, intracellular radioactivity decreased to a level not significantly different from that associated with noninfected cells. A mechanism to explain these results is proposed. It was concluded that concurrent acyclovir therapy could interfere with neuroradiological diagnosis using rlVDU, although this may not occur with all the candidate radioprobes currently under investigation.